+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen; By Indication; By Regions: Segment Forecast, 2021 - 2028

  • ID: 5261980
  • Report
  • June 2021
  • Region: Global
  • 108 Pages
  • Polaris Market Research

FEATURED COMPANIES

  • Amgen Inc. (US)
  • Bluebird Bio (US)
  • Celgene Corporation (US)
  • Cellectis (France)
  • Celyad (Belgium)
  • Gilead Sciences Inc. (US)
The global CAR-T Cell Therapy market size is expected to reach USD 15.4 billion by 2028 growing at a CAGR of 34.2% from 2021 to 2028 according to a new study. The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2021 - 2028” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.

This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients’ immune cells to fight cancer. The WBCs (white blood cells) are extracted - reengineered - injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.

According to the analysis, the potential of the market is ~ $15 billion by 2028, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 46% from 2021 to 2028.

It is estimated that US is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by US wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.

It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of US and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in US Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.

Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.

Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.
  • The publisher has segmented the CAR-T Cell Therapy market report on the basis of Target Antigens, Indications, and Region

CAR-T Cell Target Antigens Outlook (Revenue, USD Million, 2017 - 2028)

  • CD19/CD22

BCMA (B-Cell Maturation Antigen)


Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Rα2, LewisY)


CAR-T Cell Indication Outlook (Revenue, USD Million, 2017 - 2028)


Diffuse Large B-Cell Lymphoma (DLBCL)


Acute Lymphoblastic Leukemia (ALL)


Chronic Lymphocytic Leukemia (CLL)


Multiple Myeloma (MM)


Follicular Lymphoma (FL)

  • Others

CAR-T Cell Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • US
  • Europe
  • Japan
  • Rest of the World
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc. (US)
  • Bluebird Bio (US)
  • Celgene Corporation (US)
  • Cellectis (France)
  • Celyad (Belgium)
  • Gilead Sciences Inc. (US)
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders

2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation

3. CAR-T Cell Therapy Market - Premium Insights
3.1. CAR-T Cell Therapy- Industry snapshot
3.2. CAR-T Cell Therapy- Ecosystem analysis
3.3. CAR-T Cell Therapy Market dynamics
3.3.1. CAR-T Cell Therapy- Market Forces
3.3.1.1. CAR-T Cell Therapy Market driver analysis
3.3.1.2. CAR-T Cell Therapy Market restraint/challenges analysis
3.3.1.3. CAR-T Cell Therapy Market opportunity analysis
3.4. Industry analysis - Porter's five force analysis
3.5. CAR-T Cell Therapy Market PEST analysis, 2020
3.6. CAR-T Cell Therapy Industry trends
3.7. Competitive Ranking Analysis
3.8. Timeline of CAR-T Cell Therapy Development
3.9. CAR-T Cell Manufacturing Process
3.10. Side-effects of CAR-T Cell
3.11. Antigens targeting solid tumors
3.12. Clinical trials Landscape for CAR-T
3.13. Commercial Landscape (Mergers & Acquisitions, Partnerships & Collaborations)
3.14. New Innovations in CAR-T therapies

4. CAR-T Cell Therapy Market Size and Forecast 2017 - 2028 by Target Antigen
4.1. Key findings
4.2. CD19/CD22
4.2.1. Global CD19/CD22 market estimates & forecast, 2017 - 2028
4.2.2. Global CD19/CD22 market estimates & forecast, by region, 2017 - 2028
4.3. BCMA (B-Cell Maturation Antigen)
4.3.1. Global BCMA market estimates & forecast, 2017 - 2028
4.3.2. Global BCMA market estimates & forecast, by region, 2017 - 2028
4.4. Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)
4.4.1. Global Other Target Antigen market estimates & forecast, 2017 - 2028
4.4.2. Global Other Target Antigen market estimates & forecast, by region, 2017 - 2028

5. CAR-T Cell Therapy Market Size and Forecast by Indication
5.1. Key findings
5.2. Diffuse Large B-Cell Lymphoma (DLBCL)
5.2.1. Global DLBCL market estimates & forecast, 2017 - 2028
5.2.2. Global DLBCL market estimates & forecast, by region, 2017 - 2028
5.3. Acute Lymphoblastic Leukemia (ALL)
5.3.1. Global ALL market estimates & forecast, 2017 - 2028
5.3.2. Global ALL market estimates & forecast, by region, 2017 - 2028
5.4. Chronic Lymphocytic Leukemia (CLL)
5.4.1. Global CLL market estimates & forecast, 2017 - 2028
5.4.2. Global CLL market estimates & forecast, by region, 2017 - 2028
5.5. Multiple Myeloma (MM)
5.5.1. Global MM market estimates & forecast, 2017 - 2028
5.5.2. Global MM market estimates & forecast, by region, 2017 - 2028
5.6. Follicular Lymphoma (FL)
5.6.1. Global FL market estimates & forecast, 2017 - 2028
5.6.2. Global FL market estimates & forecast, by region, 2017 - 2028
5.7. Others
5.7.1. Global Other indications market estimates & forecast, 2017 - 2028
5.7.2. Global Other indications market estimates & forecast, by region, 2017 - 2028

6. CAR-T Cell Therapy Market Size and Forecast by Regions
6.1. Key findings
6.2. U.S.
6.2.1. U.S. CAR-T Cell Therapy Market by Target Antigen, 2017-2028
6.2.2. U.S. CAR-T Cell Therapy Market by Indication, 2017 - 2028
6.3. Europe
6.3.1. Europe CAR-T Cell Therapy Market by Target Antigen, 2017 - 2028
6.3.2. Europe CAR-T Cell Therapy Market by Indication, 2017 - 2028
6.4. Japan
6.4.1. Japan CAR-T Cell Therapy Market by Target Antigen, 2017 - 2028
6.4.2. Japan CAR-T Cell Therapy Market by Indication, 2017 - 2028
6.5. Rest of the World
6.5.1. RoW CAR-T Cell Therapy Market by Target Antigen, 2017 - 2028
6.5.2. RoW CAR-T Cell Therapy Market by Indication, 2017 - 2028

7. Company Profiles
7.1. Amgen Inc. (US)
7.1.1. Overview
7.1.2. Financials
7.1.3. Product Benchmarking
7.1.4. Recent Developments
7.2. Bellicum Pharmaceuticals, Inc. (US)
7.2.1. Overview
7.2.2. Financials
7.2.3. Product Benchmarking
7.2.4. Recent Developments
7.3. Bluebird Bio (US)
7.3.1. Overview
7.3.2. Financials
7.3.3. Product Benchmarking
7.3.4. Recent Developments
7.4. Caribou Biosciences, Inc. (US)
7.4.1. Overview
7.4.2. Financials
7.4.3. Product Benchmarking
7.4.4. Recent Developments
7.5. Celgene Corporation (US) (acquired by Bristol-Myers Squibb)
7.5.1. Overview
7.5.2. Financials
7.5.3. Product Benchmarking
7.5.4. Recent Developments
7.6. Cellectis (France)
7.6.1. Overview
7.6.2. Financials
7.6.3. Product Benchmarking
7.6.4. Recent Developments
7.7. Celyad (Belgium)
7.7.1. Overview
7.7.2. Financials
7.7.3. Product Benchmarking
7.7.4. Recent Developments
7.8. Gilead Sciences, Inc. (US)
7.8.1. Overview
7.8.2. Financials
7.8.3. Product Benchmarking
7.8.4. Recent Developments
7.9. Intellia Therapeutics (US)
7.9.1. Overview
7.9.2. Financials
7.9.3. Product Benchmarking
7.9.4. Recent Developments
7.10. Johnson & Johnson (US)
7.10.1. Overview
7.10.2. Financials
7.10.3. Product Benchmarking
7.10.4. Recent Developments
7.11. Mereck KGaA (Germany)
7.11.1. Overview
7.11.2. Financials
7.11.3. Product Benchmarking
7.11.4. Recent Developments
7.12. Nanjing Legend Biotechnology Co., Ltd. (China)
7.12.1. Overview
7.12.2. Financials
7.12.3. Product Benchmarking
7.12.4. Recent Developments
7.13. Noile-Immune Biotech (Japan)
7.13.1. Overview
7.13.2. Financials
7.13.3. Product Benchmarking
7.13.4. Recent Developments
7.14. Novartis International AG (Swiss)
7.14.1. Overview
7.14.2. Financials
7.14.3. Product Benchmarking
7.14.4. Recent Developments
7.15. Pfizer Inc. (US)
7.15.1. Overview
7.15.2. Financials
7.15.3. Product Benchmarking
7.15.4. Recent Developments
7.16. Sangamo Therapeutics, Inc. (US)
7.16.1. Overview
7.16.2. Financials
7.16.3. Product Benchmarking
7.16.4. Recent Developments
7.17. Servier Laboratories (France)
7.17.1. Overview
7.17.2. Financials
7.17.3. Product Benchmarking
7.17.4. Recent Developments
Note: Product cover images may vary from those shown
  • Bluebird Bio (US)
  • Celgene Corporation (US)
  • Gilead Sciences Inc. (US)
  • Cellectis (France)
  • Servier Laboratories (France)
  • Pfizer Inc. (US)
  • Mereck KGaA (Germany)
  • Amgen Inc. (US)
  • Intellia Therapeutics (US)
  • Novartis International AG (Swiss)
  • Caribou Biosciences Inc. (US)
  • Celyad (Belgium)
  • Bellicum Pharmaceuticals Inc. (US)
  • Noile-Immune Biotech (Japan)
  • Nanjing Legend Biotechnology Co. Ltd. (China)
  • Johnson & Johnson (US)
  • Sangamo Therapeutics Inc. (US)
Note: Product cover images may vary from those shown
Adroll
adroll